ToolGen (XKRX:199800) Debt-to-Asset : 0.19 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is ToolGen Debt-to-Asset?

ToolGen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩13,897.1 Mil. ToolGen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩116.7 Mil. ToolGen's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩75,478.5 Mil. ToolGen's debt to asset for the quarter that ended in Dec. 2024 was 0.19.

ToolGen Debt-to-Asset Historical Data

The historical data trend for ToolGen's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ToolGen Debt-to-Asset Chart

ToolGen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.65

0.19

ToolGen Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.65	0.68	0.73	0.77	0.19

Competitive Comparison of ToolGen's Debt-to-Asset

For the Biotechnology subindustry, ToolGen's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ToolGen's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ToolGen's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ToolGen's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

ToolGen Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ToolGen's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13897.097	+	116.703)	/	75478.506
	=	0.19

ToolGen's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13897.097	+	116.703)	/	75478.506
	=	0.19

ToolGen (XKRX:199800) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ToolGen Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ToolGen's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ToolGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ToolGen Inc (XKRX:199800) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

KOR-collar Gasan Digital Valley 1 to 219 digital Byeoksan, 6th 1204 No. ENG No. 1204, Byucksan Digital Valley 6-cha, 219 Gasan Digital 1-ro, Geumcheon-gu, Seoul, KOR

Website

http://www.toolgen.com

ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.

ToolGen Headlines

No Headlines